Therapy of acute hepatitis C with interferon: How good is it really?
dc.contributor.author | Gumucio, Jorge J. | en_US |
dc.contributor.author | Rakela, Jorge | en_US |
dc.contributor.author | Douglas, David D. | en_US |
dc.date.accessioned | 2006-04-28T16:55:18Z | |
dc.date.available | 2006-04-28T16:55:18Z | |
dc.date.issued | 1992-08 | en_US |
dc.identifier.citation | Gumucio, Jorge J.; Rakela, Jorge; Douglas, David D. (1992)."Therapy of acute hepatitis C with interferon: How good is it really?." Hepatology 16(2): 497-498. <http://hdl.handle.net/2027.42/38380> | en_US |
dc.identifier.issn | 0270-9139 | en_US |
dc.identifier.issn | 1527-3350 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/38380 | |
dc.description.abstract | To test whether interferon can prevent acute non-A, non-B hepatitis from becoming chronic, a prospective controlled trial was conducted in 25 patients; 11 were treated for an average of 30 days with a mean of 52 megaunits of interferon and 14 acted as controls. 4 patients in the treatment group who continued to have raised serum aminotransferase concentrations after a year's follow-up were given a second course of interferon. Follow-up at 3 years has revealed that all but 1 of those treated showed normal serum aminotransferase, whereas only 3 controls showed such change (p < 0.02). Serum hepatitis C virus RNA became undetectable in 10 of 11 treated and in only 1 of 12 control patients, which suggests that interferon prevents the progression of acute non-A, non-B hepatitis to chronicity by eradicating HCV. | en_US |
dc.format.extent | 272688 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | W.B. Saunders | en_US |
dc.publisher | Wiley Periodiocals, Inc. | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Hepatology | en_US |
dc.title | Therapy of acute hepatitis C with interferon: How good is it really? | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Internal Medicine Division of Gastroenterology (111D) VA Medical Center/University of Michigan Ann Arbor, Michigan 48105 | en_US |
dc.contributor.affiliationother | Mayo Clinic Rochester, Minnesota 55905 | en_US |
dc.contributor.affiliationother | Mayo Clinic Rochester, Minnesota 55905 | en_US |
dc.identifier.pmid | 1639358 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/38380/1/1840160232_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/hep.1840160232 | en_US |
dc.identifier.source | Hepatology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.